Part3_Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML: synergy with gilteritinib

Published: 13 Dec 2019 | Version 1 | DOI: 10.17632/xzjmk67vnc.1
Contributor(s):

Description of this data

Treatment of acute myeloid leukemia (AML) remains inefficient due to drug resistance and relapse, particularly in patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD). Marine-derived natural products have recently been used for drug development against AML. We show here that petromurin C, isolated from the culture extract of the marine-derived fungus Aspergillus candidus KUFA0062, which was isolated from the marine sponge Epipolasis sp., induces early autophagy followed by apoptotic cell death via activation of the intrinsic cell death pathway concomitant with mitochondrial stress and downregulation of Mcl-1 in FLT3-ITD mutated MV4-11 cells. Moreover, petromurin C synergized with the clinically-used FLT3 inhibitor gilteritinib at sub-toxic concentrations. Altogether our results suggest that petromurin C could act as an anti-leukemic agent alone or in combination with gilteritinib.

Experiment data files

  • Figure 5
    Cite
    • A_Diff Quik of compound 2b
      Cite
      • MV4-11_2b_Diff Quik_1st
        Cite
        • 0_24h
          Cite
        • 0_8h
          Cite
        • 2b 10_24h
          Cite
        • 2b 10_8h
          Cite
        • 2b 30_24h
          Cite
        • 2b 30_8h
          Cite
        • 2b 50_24h
          Cite
        • 2b 50_8h
          Cite
        • eto_4h
          Cite
      • MV4-11_2b_Diff Quik_2nd
        Cite
        • 0_24h
          Cite
        • 0_8h
          Cite
        • 2b 10_24h
          Cite
        • 2b 10_8h
          Cite
        • 2b 30_24h
          Cite
        • 2b 30_8h
          Cite
        • 2b 50_24h
          Cite
        • 2b 50_8h
          Cite
        • eto_4h
          Cite
      • MV4-11_2b_Diff Quik_3rd
        Cite
        • 0_24h
          Cite
        • 0_8h
          Cite
        • 2b 10_24h
          Cite
        • 2b 10_8h
          Cite
        • 2b 30_24h
          Cite
        • 2b 30_8h
          Cite
        • 2b 50_24h
          Cite
        • 2b 50_8h
          Cite
        • eto_4h
          Cite
      • Representatives
        Cite
    • B_TEM images
      Cite
      • 0_24h
        Cite
        • 0_1
          Cite
        • 0_2
          Cite
        • 0_3
          Cite
        • 0_4
          Cite
        • 0_5
          Cite
        • 0_6
          Cite
        • 0_7
          Cite
      • 2b 30_24h
        Cite
        • 2b 30_24h_1
          Cite
        • 2b 30_24h_2
          Cite
        • 2b 30_24h_3
          Cite
        • 2b 30_24h_4
          Cite
        • 2b 30_24h_5
          Cite
      • 2b 30_4h
        Cite
        • 2b 30_4h_1
          Cite
        • 2b 30_4h_2
          Cite
        • 2b 30_4h_3
          Cite
        • 2b 30_4h_4
          Cite
        • 2b 30_4h_5
          Cite
      • 2b 30_8h
        Cite
        • 2b 30_8h_1
          Cite
        • 2b 30_8h_2
          Cite
        • 2b 30_8h_3
          Cite
        • 2b 30_8h_4
          Cite
        • 2b 30_8h_5
          Cite
      • Representatives
        Cite
  • Figure 6
    Cite
    • A_Diff Quik of inhibitor pre-treatment and compound 2b
      Cite
      • MV4-11_2b 50+baf-a1
        Cite
        • MV4-11_Diff Quik_2b+baf-a1_1st
          Cite
          • 0_10h
            Cite
          • 2b 50+baf_10h
            Cite
          • 2b 50_8h
            Cite
        • MV4-11_Diff Quik_2b+baf-a1_2nd
          Cite
          • 0_10h
            Cite
          • 2b 50+baf_10h
            Cite
          • 2b 50_8h
            Cite
        • MV4-11_Diff Quik_2b+baf-a1_3rd
          Cite
          • 0_10h
            Cite
          • 2b 50+baf_10h
            Cite
          • 2b 50_8h
            Cite
        • Representatives
          Cite
      • MV4-11_2b 50+z-vad
        Cite
        • MV4-11_2b+z-vad_1st
          Cite
          • 0_24h
            Cite
          • 2b 50+zvad_25h
            Cite
          • 2b 50+zvad_9h
            Cite
          • 2b 50_24h
            Cite
          • 2b 50_8h
            Cite
        • MV4-11_2b+z-vad_2nd
          Cite
          • 0_24h
            Cite
          • 2b 50+zvad_25h
            Cite
          • 2b 50+zvad_9h
            Cite
          • 2b 50_24h
            Cite
          • 2b 50_8h
            Cite
        • MV4-11_2b+z-vad_3rd
          Cite
          • 0_24h
            Cite
          • 2b 50+zvad_25h
            Cite
          • 2b 50+zvad_9h
            Cite
          • 2b 50_24h
            Cite
          • 2b 50_8h
            Cite
        • Representatives
          Cite
    • B_Western Blots
      Cite
      • LC3B
        Cite
        • Beta actin for LC3B_1st
          Cite
        • Beta actin for LC3B_2nd
          Cite
        • Beta actin for LC3B_3rd
          Cite
        • LC3B_1st
          Cite
        • LC3B_2nd
          Cite
        • LC3B_3rd
          Cite
      • Representative pictures
        Cite
        • beta actin
          Cite
        • LC3B
          Cite
    • C_Quantification of western blots of LC3B
      Cite
    • E_Hoechst and PI of 2b+baf-a1
      Cite
      • Hoechst and PI of 2b+baf-a1_1st
        Cite
        • 0_10h_1st
          Cite
        • 2b 30+baf_10h_1st
          Cite
        • 2b 30_8h_1st
          Cite
        • baf_10h_1st
          Cite
      • Hoechst and PI of 2b+baf-a1_2nd
        Cite
        • 0_10h_2nd
          Cite
        • 2b 30+baf_10h_2nd
          Cite
        • 2b 30_8h_2nd
          Cite
        • baf_10h_2nd
          Cite
      • Hoechst and PI of 2b+baf-a1_3rd
        Cite
        • 0_10h_2nd
          Cite
        • 2b 30+baf_10h_2nd
          Cite
        • 2b 30_8h
          Cite
        • baf_10h_3rd
          Cite
      • Representatives
        Cite
  • Figure 7
    Cite
    • A_MMP FACs graphs
      Cite
      • MV4-11_MMP_1st
        Cite
      • MV4-11_MMP_2nd
        Cite
      • MV4-11_MMP_3rd
        Cite
      • Representatives
        Cite
    • B_MMP loss calculation
      Cite
    • C_Seahorse mito stress assay analysis
      Cite
    • C_Seahorse mito stress assay graph
      Cite
    • D_ATP of compound 2b in MV4-11
      Cite
  • Figure 8
    Cite
    • A. Trypan Blue Assay of Gilteritinib
      Cite
      • MV4-11
        Cite
      • U937
        Cite
    • B. Hoechst and PI of combination of 2b and Gilteritinib
      Cite
      • Combi_MV4-11_1st
        Cite
        • 0_1st
          Cite
        • 2b 30 + G 100_1st
          Cite
        • 2b 30 + G 250_1st
          Cite
        • 2b 30 + G 500_1st
          Cite
        • 2b 30_1st
          Cite
        • 2b 5 + G 100_1st
          Cite
        • 2b 5 + G 250_1st
          Cite
        • 2b 5 + G 500_1st
          Cite
        • 2b 50 + G 100_1st
          Cite
        • 2b 50 + G 250_1st
          Cite
        • 2b 50 + G 500_1st
          Cite
        • 2b 50_1st
          Cite
        • 2b 5_1st
          Cite
        • G 100_1st
          Cite
        • G 250_1st
          Cite
        • G 500_1st
          Cite
      • Combi_MV4-11_2nd
        Cite
        • 0_2nd
          Cite
        • 2b 30 + G 100_2nd
          Cite
        • 2b 30 + G 250_2nd
          Cite
        • 2b 30 + G 500_2nd
          Cite
        • 2b 30_2nd
          Cite
        • 2b 5 + G 100_2nd
          Cite
        • 2b 5 + G 250_2nd
          Cite
        • 2b 5 + G 500_2nd
          Cite
        • 2b 50 + G 100_2nd
          Cite
        • 2b 50 + G 250_2nd
          Cite
        • 2b 50 + G 500_2nd
          Cite
        • 2b 50_2nd
          Cite
        • 2b 5_2nd
          Cite
        • G 100
          Cite
        • G 250
          Cite
        • G 500
          Cite
        • New folder.1
          Cite
      • Combi_MV4-11_3rd
        Cite
        • 0_3rd
          Cite
        • 2b 30 + G 100_3rd
          Cite
        • 2b 30 + G 250_3rd
          Cite
        • 2b 30 + G 500_3rd
          Cite
        • 2b 30_3rd
          Cite
        • 2b 5 + G 100_3rd
          Cite
        • 2b 5 + G 250_3rd
          Cite
        • 2b 5 + G 500_3rd
          Cite
        • 2b 50 + G 100_3rd
          Cite
        • 2b 50 + G 250_3rd
          Cite
        • 2b 50 + G 500_3rd
          Cite
        • 2b 50_3rd
          Cite
        • 2b 5_3rd
          Cite
        • G 100
          Cite
        • G 250
          Cite
        • G 500
          Cite
      • Representatives
        Cite
    • C_CFA of combination of 2b 30uM and Gilteritinib 1nM
      Cite
      • MV4-11_cfa_combination_2b30+g1_1st
        Cite
      • MV4-11_cfa_combination_2b30+g1_2nd
        Cite
      • MV4-11_cfa_combination_2b30+g1_3rd
        Cite
      • Representatives
        Cite
    • Table 4. Compusyn combination index in suspension cultures
      Cite
    • Table 5. Compusyn combination index in colony formation assays
      Cite
  • Figure 9
    Cite
    • A. Diff Quik of combination of 2b and Gilteritinib
      Cite
      • MV4-11_combi_Diff Quik_1st
        Cite
        • 0_1st
          Cite
        • 2b 30 + G 250_1st
          Cite
        • 2b 30 + G 500_1st
          Cite
        • 2b 30_1st
          Cite
        • G 250_1st
          Cite
        • G 500_1st
          Cite
      • MV4-11_combi_Diff Quik_2nd
        Cite
        • 0_2nd
          Cite
        • 2b 30 + G 250_2nd
          Cite
        • 2b 30 + G 500_2nd
          Cite
        • 2b 30_2nd
          Cite
        • G 250
          Cite
        • G 500
          Cite
      • MV4-11_combi_Diff Quik_3rd
        Cite
        • 0_3rd
          Cite
        • 2b 30 + G 250_3rd
          Cite
        • 2b 30 + G 500_3rd
          Cite
        • 2b 30_3rd
          Cite
        • G 250_3rd
          Cite
        • G 500_3rd
          Cite
      • Representatives
        Cite
    • B. TEM images of combination treatment
      Cite
      • 2b 30uM + G250_24h
        Cite
        • 2b 30uM + G250_24h_1
          Cite
        • 2b 30uM + G250_24h_2
          Cite
        • 2b 30uM + G250_24h_3
          Cite
        • 2b 30uM + G250_24h_4
          Cite
        • 2b 30uM + G250_24h_5
          Cite
      • 2b 30uM_24h
        Cite
        • 2b 30uM_24h_1
          Cite
        • 2b 30uM_24h_2
          Cite
        • 2b 30uM_24h_3
          Cite
        • 2b 30uM_24h_4
          Cite
        • 2b 30uM_24h_5
          Cite
    • Table 6. Comparison for the number of vacuoles between 2b alone and a combination
      Cite
  • Supplementary Figures
    Cite
    • Supplementary Figure 1
      Cite
      • Comparison for the number of vacuoles
        Cite
        • 0 (24h)
          Cite
          • 0 (24h)_1
            Cite
          • 0 (24h)_2
            Cite
          • 0 (24h)_3
            Cite
          • 0 (24h)_4
            Cite
        • 2b 30uM (24h)
          Cite
          • 2b 30uM (24h)_1
            Cite
          • 2b 30uM (24h)_2
            Cite
          • 2b 30uM (24h)_3
            Cite
          • 2b 30uM (24h)_4
            Cite
          • 2b 30uM (24h)_5
            Cite
        • 2b 30uM (4h)
          Cite
          • 2b 30uM (4h)_1
            Cite
          • 2b 30uM (4h)_2
            Cite
          • 2b 30uM (4h)_3
            Cite
          • 2b 30uM (4h)_4
            Cite
        • 2b 30uM (8h)
          Cite
          • 2b 30uM (8h)_1
            Cite
          • 2b 30uM (8h)_2
            Cite
          • 2b 30uM (8h)_3
            Cite
          • 2b 30uM (8h)_4
            Cite
          • 2b 30uM (8h)_5
            Cite
    • Supplementary Figure 2
      Cite
      • p62
        Cite
        • beta actin for p62_1st
          Cite
        • beta actin for p62_2nd
          Cite
        • beta actin for p62_3rd
          Cite
        • p 62_1st
          Cite
        • p 62_2nd
          Cite
        • p 62_3rd
          Cite
      • Quantification of western blots of p62
        Cite
      • Representatives
        Cite
        • beta actin
          Cite
        • p62
          Cite
    • Supplementary Figure 3
      Cite
      • S3.A_Pictures of Hoechst and PI of z-vad pretreatment and Gilteritinib
        Cite
        • Gilteritinib_24h_1st
          Cite
          • 0+zvad_24h
            Cite
          • 0_24h
            Cite
          • 100+zvad_24h
            Cite
          • 1000+zvad_24h
            Cite
          • 1000_24h
            Cite
          • 100_24h
            Cite
          • 250+zvad_24h
            Cite
          • 250_24h
            Cite
          • 50+zvad_24h
            Cite
          • 500+zvad_24h
            Cite
          • 500_24h
            Cite
          • 50_24h
            Cite
          • 750+zvad_24h
            Cite
          • 750_24h
            Cite
          • eto+zvad_4h
            Cite
          • eto_4h
            Cite
        • Gilteritinib_24h_2nd
          Cite
          • 0+zvad_24h
            Cite
          • 0_24h
            Cite
          • 100+zvad_24h
            Cite
          • 1000+zvad_24h
            Cite
          • 1000_24h
            Cite
          • 100_24h
            Cite
          • 250+zvad_24h
            Cite
          • 250_24h
            Cite
          • 50+zvad_24h
            Cite
          • 500+zvad_24h
            Cite
          • 500_24h
            Cite
          • 50_24h
            Cite
          • 750+zvad_24h
            Cite
          • 750_24h
            Cite
        • Gilteritinib_24h_3rd
          Cite
          • 0+zvad_24h
            Cite
          • 0_24h
            Cite
          • 100+zvad_24h
            Cite
          • 1000+zvad_24h
            Cite
          • 1000_24h
            Cite
          • 100_24h
            Cite
          • 250+zvad_24h
            Cite
          • 250_24h
            Cite
          • 50+zvad_24h
            Cite
          • 500+zvad_24h
            Cite
          • 500_24h
            Cite
          • 50_24h
            Cite
          • 750+zvad_24h
            Cite
          • 750_24h
            Cite
        • Representatives
          Cite
      • S3.B_Qunatifiaction of Hoechst and PI of z-vad pretreatment and Gilteritinib
        Cite
    • Supplementary Figure 4
      Cite
      • S4.A_Pictures of CFA of combination of 2b and Gilteritinib
        Cite
        • CFA_Combi for combi index_1st
          Cite
        • CFA_Combi for combi index_2nd
          Cite
        • CFA_Combi for combi index_3rd
          Cite
        • Representatives
          Cite
      • S4.B_Qunatification of CFA of combination of 2b and Gilteritinib
        Cite
      • S4.C_CI values of CFA of combination of 2b and Gilteritinib
        Cite

Latest version

  • Version 1

    2019-12-13

    Published: 2019-12-13

    DOI: 10.17632/xzjmk67vnc.1

    Cite this dataset

    Ha, You Na (2019), “Part3_Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML: synergy with gilteritinib”, Mendeley Data, v1 http://dx.doi.org/10.17632/xzjmk67vnc.1

Statistics

Views: 5226
Downloads: 0

Categories

Health Sciences

Licence

CC BY 4.0 Learn more

The files associated with this dataset are licensed under a Creative Commons Attribution 4.0 International licence.

What does this mean?
You can share, copy and modify this dataset so long as you give appropriate credit, provide a link to the CC BY license, and indicate if changes were made, but you may not do so in a way that suggests the rights holder has endorsed you or your use of the dataset. Note that further permission may be required for any content within the dataset that is identified as belonging to a third party.

Report